COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that interim results at the one year time point for the Company’s Phase I trial evaluating Prochymal™ for the treatment of heart attack patients continued to demonstrate a strong safety profile and statistically significant improvement in heart function. Based upon the positive results from this 53-patient, double-blind, placebo-controlled trial, the Company has received approval from the Food and Drug Administration (FDA) to initiate a Phase II trial.
